Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease

International Urology and Nephrology

Volumn 37, Issue 2, 2005, Pages 395-402

  Li, Shuling ^a   Foley, Robert N ^a,b   Collins, Allan J ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anemia; Chronic kidney disease; Medicare; Outcomes

Indexed keywords

AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEGRO; OUTCOMES RESEARCH; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO;

AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; RETROSPECTIVE STUDIES;

EID: 25144514480     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-004-3068-2     Document Type: Article

References (41)

1. National Kidney Foundation-Dialysis Outcomes Quality Initiative. 1997 NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure Am J Kidney Dis 30 S192-S240
2. F Madore E Lowrie C Brugnara et al. 1997 Anemia in hemodialysis patients: Variables affecting this outcome predictor J Am Soc Nephrol 8 12 1921-1929 9402095
3. H Xia J Ebben J Ma A. Collins 1999 Hematocrit levels and hospitalization risks in hemodialysis patients J Am Soc Nephrol 10 1309-1316 10361870
4. AJ Collins S Li WL St Peter et al. 2001 Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% J Am Soc Nephrol 12 2465-2473 11675424
5. LP McMahon JA Johns A McKenzie et al. 1992 Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin Nephrol Dial Transplant 7 1199-1206 1337160
6. A Sikole M Polenakovic V Spirovska et al. 1993 Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients Artif Organs 17 977-984 8110072
7. RW Evans B Rader DL Manninen Cooperative Multicenter EPO Clinical Trial Group 1990 The quality of life of hemodialysis recipients treated with recombinant human erythropoietin JAMA 263 825-830 10.1001/jama.263.6.825 2404150
8. Canadian Erythropoietin Study Group 1990 Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis BMJ 300 573-578
9. ST Lillevang FB. Pedersen 1990 Quality of life of hemodialysis patients before and after erythropoietin therapy. A double-blind, randomized, placebo controlled study Ugeskr Laeger 152 2999-3002 2238169
10. The US Recombinant Human Erythropoietin Predialysis Study Group. 1991 Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients Am J Kidney Dis 18 50-59
11. LP McMahon JK. Dawborn 1992 Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin Am J Nephrol 12 162-169 1415377
12. RN Foley PS Parfrey J Morgan et al. 2000 Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 1325-1335 10.1046/j.1523-1755.2000.00289.x 10972697
13. PH Chaves B Ashar JM Guralnik LP. Fried 2002 Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc 50 1257-1264 10.1046/ j.1532-5415.2002.50313.x 12133021
14. MJ Sarnak H Tighiouart G Manjunath et al. 2002 Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study J Am Coll Cardiol 40 27-33 10.1016/S0735-1097(02)01938-1 12103252
15. TB Horwich GC Fonarow MA Hamilton et al. 2002 Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure J Am Coll Cardiol 39 11 1780-1786 10.1016/S0735-1097(02)01854-5 12039491
16. WM McClellan WD Flanders RD Langston et al. 2002 Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study J Am Soc Nephrol 13 7 1928-1936 10.1097/ 01.ASN.0000018409.45834.FA 12089390
17. M Kosiborod GL Smith MJ Radford et al. 2003 The prognostic importance of anemia in patients with heart failure Am J Med 114 112-119 10.1016/ S0002-9343(02)01498-5 12586230
18. H Tanner G Moschovitis GM Kuster et al. 2002 The prevalence of anemia in chronic heart failure Int J Cardiol 86 115-121 10.1016/ S0167-5273(02)00273-5 12400591
19. JA Ezekowitz FA McAlister PW. Armstrong 2003 Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12,065 patients with new-onset heart failure Circulation 107 223-225 10.1161/01.CIR.0000052622.51963.FC 12538418
20. AS Androne SD Katz L Lund 2003 Hemodilution is common in patients with advanced heart failure Circulation 107 226-229 10.1161/ 01.CIR.0000052623.16194.80 12538419
21. DM Mancini SD Katz CC Lang et al. 2003 Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure Circulation 107 294-299 10.1161/01.CIR.0000044914.42696.6A 12538431
22. DS Silverberg D Wexler M Blum et al. 2000 The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations J Am Coll Cardiol 35 1737-1744 10.1016/ S0735-1097(00)00613-6 10841219
23. DS Silverberg D Wexler D Sheps et al. 2001 The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study J Am Coll Cardiol 37 1775-1780 10.1016/ S0735-1097(01)01248-7 11401110
24. BC Astor P Muntner A Levin et al. 2002 Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 162 1401-1408 10.1001/archinte.162.12.1401 12076240
25. KS Kleinman SU Schweitzer ST Perdue et al. 1989 The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial Am J Kidney Dis 14 486-495 2688405
26. DA Revicki RE Brown DH Feeny et al. 1995 Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients Am J Kidney Dis 25 548-554 7702049
27. A Levin J Singer CR Thompson et al. 1996 Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention Am J Kidney Dis 27 347-354 8604703
28. A Levin CR Thompson J Ethier et al. 1999 Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin Am J Kidney Dis 34 125-134 10401026
29. DC Holland M. Lam 2000 Predictors of hospitalization and death among pre-dialysis patients: A retrospective cohort study Nephrol Dial Transplant 15 650-658 10.1093/ndt/15.5.650 10809806
30. PL Hebert LS Geiss EF Tierney et al. 1999 Identifying persons with diabetes using Medicare claims data Am J Med Qual 14 270-277 10624032
31. M Duke WH. Abelmann 1969 The hemodynamic response to chronic anemia Circulation 39 503-515 5778251
32. AM. Katz 1994 The cardiomyopathy of overload: An unnatural growth response in the hypertrophied heart Ann Intern Med 121 363-371 8042826
33. JJ Hunter KR. Chien 1999 Signaling pathways for cardiac hypertrophy and failure N Engl J Med 341 1276-1283 10.1056/NEJM199910213411706 10528039
34. C Kitiyakara J Gonin Z Massy CS. Wilcox 2000 Non-traditional cardiovascular disease risk factors in end-stage renal disease: Oxidate stress and hyperhomocysteinemia Curr Opin Nephrol Hypertens 9 477-487 10.1097/00041552-200009000-00004 10990365
35. T Grune O Sommerburg WG. Siems 2000 Oxidative stress in anemia Clin Nephrol 53 S18-S22 10746801
36. J Rossert B Fouqueray JJ. Boffa 2003 Anemia management and the delay of chronic renal failure progression J Am Soc Nephrol 14 173-177S 10.1097/ 01.ASN.0000070079.54912.B6
37. M Tepel GM der van M Statz et al. 2003 The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial Circulation 107 992-995 10.1161/ 01.CIR.0000050628.11305.30 12600912
38. M Boaz S Smetana T Weinstein et al. 2000 Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial Lancet 356 1213-1218 10.1016/S0140-6736(00)02783-5 11072938
39. D Roth RD Smith G Schulman et al. 1994 Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients Am J Kidney Dis 24 777-784 7977319
40. S Kuriyama H Tomonari H Yoshida et al. 1997 Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients Nephron 77 176-185 9346384
41. J Coresh BC Astor T Greene et al. 2003 Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 1-12 10.1053/ajkd.2003.50007 12500213